og体育
join us
CN
Home page
About Us
Profile
og体育:Affiliates/Subsidiaries
Development History
og体育:Quality Management
Contact Us
og体育:Legal Statement
Adverse Reaction Report
og体育:Science and Technology
R&D platform
og体育:R&D pipeline
og体育:Therapeutic Field
og体育:International Business
APIs
og体育:Finished Products
og体育:Medical device
og体育:Download product list
Contact
News Center
og体育:News & Trends
Public information
News & Trends
242022-11
IND acceptance by NMPA for SAL0119 tablets f𓄧or the treatment of active ankylosing spondylitis and moderate-to-𒁃severe active rheumatoid arthritis
102022-11
Tไhe marketing application of SAL0107 for the treatment of primary hypertension was aꩵccepted
102022-11
Speeding up the innovation, Sa𒁏lubris moves ✨into the era of RNA drugs
242022-10
Using AI-enabled drug di♐scovery tools, Salubris has partnered with AlphaMol to develop innoꦡvative drugs for obesity
172022-10
Clinical progress of SAL0๊108 for the treatment of primary hypertens🤪ion
132022-10
Clinical progress of SAL056 for the treatment of osteo🐎porosis
目前在第
3
页,
共有
9
页,
共有
50
条记录
第一页
上一页
1
2
3
4
5
下一页
最后一页
跳转到
页
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7fDzSfyJvbjbD",ck:"K9y7fDzSfyJvbjbD"});
谈球吧体育(中国) - 官网app下载
OG体育(中国) - 官方网站
OG体育·(中国)平台
og体育(中国)- app下载